Who Paid My Doc
Tyler Goldberg
Adult Reconstructive Orthopaedic Surgery Austin, TX Medical Doctor
NPI 1528034451 CMS profile 159658
4700 Seton Center Pkwy, Suite 200, Austin, TX 78759
General payments
$4,573,066
Research payments
$189,915
Ownership & investment interest
$0
Through program year 2025, Tyler Goldberg of Austin, TX is reported in the CMS Open Payments database as having received $4,573,066 across 589 general payments and $189,915 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 98th percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $219,386 | 75 | |
| 2024 | General | $293,614 | 85 | |
| 2023 | General | $634,210 | 83 | |
| 2023 | Research | $4,550 | 1 | |
| 2022 | General | $670,451 | 99 | |
| 2022 | Research | $350 | 1 | |
| 2021 | General | $899,331 | 85 | |
| 2021 | Research | $520 | 1 | |
| 2020 | General | $877,409 | 59 | |
| 2020 | Research | $45,565 | 10 | |
| 2019 | General | $978,665 | 103 | |
| 2019 | Research | $138,930 | 12 |
Beside peers
- Tyler Goldberg
- Adult Reconstructive Orthopaedic Surgery median
- Middle half of Adult Reconstructive Orthopaedic Surgery
- National median
In program year 2025, general payments to Tyler Goldberg were reported at $219,386. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.
Show as a table
| Year | Tyler Goldberg | Adult Reconstructive Orthopaedic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $978,665 | $1,416 | $292–$9,336 | $163 |
| 2020 | $877,409 | $647 | $141–$6,474 | $114 |
| 2021 | $899,331 | $1,073 | $211–$6,497 | $132 |
| 2022 | $670,451 | $1,217 | $236–$6,299 | $149 |
| 2023 | $634,210 | $1,082 | $246–$6,818 | $160 |
| 2024 | $293,614 | $1,575 | $323–$8,944 | $164 |
| 2025 | $219,386 | $1,406 | $318–$8,709 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 16 drugsPart D claims
1,668
Drug cost
$11,500
Branded share of claims
21.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Tranexamic Acid | Generic | 119 | $3,408 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 301 | $2,535 | |
| Meloxicam | Generic | 411 | $1,385 | |
| Methylprednisolone | Generic | 183 | $1,129 | |
| Tramadol Hcl | Generic | 289 | $806 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 47 | $559 | |
| Celecoxib | Generic | 29 | $471 | |
| Cephalexin | Generic | 29 | $367 | |
| Diclofenac Sodium | Generic | 24 | $263 | |
| Clindamycin Hcl | Generic | 18 | $126 |
The 10 drugs with the highest cost, of 16 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 54 billing codesPaid by Medicare
$319,824
Medicare patients
630
Services billed
3,854
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 68% | |
| Ischemic heart disease | 28% | |
| Diabetes | 19% | |
| Depression | 19% | |
| Osteoporosis | 18% | |
| Atrial fibrillation | 15% | |
| Cancer | 13% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 104 | 610 | $458 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
614 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adult Reconstructive Orthopaedic Surgery in Texas
Antonia Chen
Adult Reconstructive Orthopaedic Surgery · Dallas, TX
John Barrington
Adult Reconstructive Orthopaedic Surgery · Plano, TX
Roger Emerson
Adult Reconstructive Orthopaedic Surgery · Plano, TX
Donald Hohman
Adult Reconstructive Orthopaedic Surgery · Dallas, TX
Steven Weeden
Adult Reconstructive Orthopaedic Surgery · Fort Worth, TX
Marcus Ford
Adult Reconstructive Orthopaedic Surgery · Fort Worth, TX
Related records
Adult Reconstructive Orthopaedic Surgery in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Adult Reconstructive Orthopaedic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.